MTHFR C677T and MTR A2756G polymorphisms and the homocysteine lowering efficacy of different doses of folic acid in hypertensive Chinese adults

Xianhui Qin, Jianping Li, Yimin Cui, Zeyuan Liu, Zhigang Zhao, Junbo Ge, Deming Guan, Jian Hu, Xiping Xu, Yanni Wang, Fumin Zhang, Xin Xu, Xiaobin Wang, Yong Huo

Research output: Contribution to journalArticle

Abstract

Background: This study aimed to investigate if the homocysteine-lowering efficacy of two commonly used physiological doses (0.4 mg/d and 0.8 mg/d) of folic acid (FA) can be modified by individual methylenetetrahydrofolate reductase (MTHFR) C677T and/or methionine synthase (MTR) A2756G polymorphisms in hypertensive Chinese adults. Methods. A total of 480 subjects with mild or moderate essential hypertension were randomly assigned to three treatment groups: 1) enalapril only (10 mg, control group); 2) enalapril-FA tablet [10:0.4 mg (10 mg enalapril combined with 0.4 mg of FA), low FA group]; and 3) enalapril-FA tablet (10:0.8 mg, high FA group), once daily for 8 weeks. Results: After 4 or 8 weeks of treatment, homocysteine concentrations were reduced across all genotypes and FA dosage groups, except in subjects with MTR 2756AG /GG genotype in the low FA group at week 4. However, compared to subjects with MTHFR 677CC genotype, homocysteine concentrations remained higher in subjects with CT or TT genotype in the low FA group (P <0.05 for either of these genotypes) and TT genotype in the high FA group (P <0.05). Furthermore, subjects with TT genotype showed a greater homocysteine-lowering response than did subjects with CC genotype in the high FA group (mean percent reduction of homocysteine at week 8: CC 10.8% vs. TT: 22.0%, P = 0.005), but not in the low FA group (CC 9.9% vs. TT 11.2%, P = 0.989). Conclusions: This study demonstrated that MTHFR C677T polymorphism can not only affect homocysteine concentration at baseline and post-FA treatment, but also can modify therapeutic responses to various dosages of FA supplementation.

Original languageEnglish (US)
Article number2
JournalNutrition Journal
Volume11
Issue number1
DOIs
StatePublished - 2012
Externally publishedYes

Fingerprint

Methylenetetrahydrofolate Reductase (NADPH2)
Homocysteine
Folic Acid
Genotype
Enalapril
Tablets
5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase
Therapeutics

Keywords

  • Folic acid supplementation
  • Homocysteine-lowering efficacy
  • MTHFR C677T polymorphism
  • MTR A2756G polymorphism

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics

Cite this

MTHFR C677T and MTR A2756G polymorphisms and the homocysteine lowering efficacy of different doses of folic acid in hypertensive Chinese adults. / Qin, Xianhui; Li, Jianping; Cui, Yimin; Liu, Zeyuan; Zhao, Zhigang; Ge, Junbo; Guan, Deming; Hu, Jian; Xu, Xiping; Wang, Yanni; Zhang, Fumin; Xu, Xin; Wang, Xiaobin; Huo, Yong.

In: Nutrition Journal, Vol. 11, No. 1, 2, 2012.

Research output: Contribution to journalArticle

Qin, Xianhui ; Li, Jianping ; Cui, Yimin ; Liu, Zeyuan ; Zhao, Zhigang ; Ge, Junbo ; Guan, Deming ; Hu, Jian ; Xu, Xiping ; Wang, Yanni ; Zhang, Fumin ; Xu, Xin ; Wang, Xiaobin ; Huo, Yong. / MTHFR C677T and MTR A2756G polymorphisms and the homocysteine lowering efficacy of different doses of folic acid in hypertensive Chinese adults. In: Nutrition Journal. 2012 ; Vol. 11, No. 1.
@article{033dd4cb614242cb885ee7764cb8b4c5,
title = "MTHFR C677T and MTR A2756G polymorphisms and the homocysteine lowering efficacy of different doses of folic acid in hypertensive Chinese adults",
abstract = "Background: This study aimed to investigate if the homocysteine-lowering efficacy of two commonly used physiological doses (0.4 mg/d and 0.8 mg/d) of folic acid (FA) can be modified by individual methylenetetrahydrofolate reductase (MTHFR) C677T and/or methionine synthase (MTR) A2756G polymorphisms in hypertensive Chinese adults. Methods. A total of 480 subjects with mild or moderate essential hypertension were randomly assigned to three treatment groups: 1) enalapril only (10 mg, control group); 2) enalapril-FA tablet [10:0.4 mg (10 mg enalapril combined with 0.4 mg of FA), low FA group]; and 3) enalapril-FA tablet (10:0.8 mg, high FA group), once daily for 8 weeks. Results: After 4 or 8 weeks of treatment, homocysteine concentrations were reduced across all genotypes and FA dosage groups, except in subjects with MTR 2756AG /GG genotype in the low FA group at week 4. However, compared to subjects with MTHFR 677CC genotype, homocysteine concentrations remained higher in subjects with CT or TT genotype in the low FA group (P <0.05 for either of these genotypes) and TT genotype in the high FA group (P <0.05). Furthermore, subjects with TT genotype showed a greater homocysteine-lowering response than did subjects with CC genotype in the high FA group (mean percent reduction of homocysteine at week 8: CC 10.8{\%} vs. TT: 22.0{\%}, P = 0.005), but not in the low FA group (CC 9.9{\%} vs. TT 11.2{\%}, P = 0.989). Conclusions: This study demonstrated that MTHFR C677T polymorphism can not only affect homocysteine concentration at baseline and post-FA treatment, but also can modify therapeutic responses to various dosages of FA supplementation.",
keywords = "Folic acid supplementation, Homocysteine-lowering efficacy, MTHFR C677T polymorphism, MTR A2756G polymorphism",
author = "Xianhui Qin and Jianping Li and Yimin Cui and Zeyuan Liu and Zhigang Zhao and Junbo Ge and Deming Guan and Jian Hu and Xiping Xu and Yanni Wang and Fumin Zhang and Xin Xu and Xiaobin Wang and Yong Huo",
year = "2012",
doi = "10.1186/1475-2891-11-2",
language = "English (US)",
volume = "11",
journal = "Nutrition Journal",
issn = "1475-2891",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - MTHFR C677T and MTR A2756G polymorphisms and the homocysteine lowering efficacy of different doses of folic acid in hypertensive Chinese adults

AU - Qin, Xianhui

AU - Li, Jianping

AU - Cui, Yimin

AU - Liu, Zeyuan

AU - Zhao, Zhigang

AU - Ge, Junbo

AU - Guan, Deming

AU - Hu, Jian

AU - Xu, Xiping

AU - Wang, Yanni

AU - Zhang, Fumin

AU - Xu, Xin

AU - Wang, Xiaobin

AU - Huo, Yong

PY - 2012

Y1 - 2012

N2 - Background: This study aimed to investigate if the homocysteine-lowering efficacy of two commonly used physiological doses (0.4 mg/d and 0.8 mg/d) of folic acid (FA) can be modified by individual methylenetetrahydrofolate reductase (MTHFR) C677T and/or methionine synthase (MTR) A2756G polymorphisms in hypertensive Chinese adults. Methods. A total of 480 subjects with mild or moderate essential hypertension were randomly assigned to three treatment groups: 1) enalapril only (10 mg, control group); 2) enalapril-FA tablet [10:0.4 mg (10 mg enalapril combined with 0.4 mg of FA), low FA group]; and 3) enalapril-FA tablet (10:0.8 mg, high FA group), once daily for 8 weeks. Results: After 4 or 8 weeks of treatment, homocysteine concentrations were reduced across all genotypes and FA dosage groups, except in subjects with MTR 2756AG /GG genotype in the low FA group at week 4. However, compared to subjects with MTHFR 677CC genotype, homocysteine concentrations remained higher in subjects with CT or TT genotype in the low FA group (P <0.05 for either of these genotypes) and TT genotype in the high FA group (P <0.05). Furthermore, subjects with TT genotype showed a greater homocysteine-lowering response than did subjects with CC genotype in the high FA group (mean percent reduction of homocysteine at week 8: CC 10.8% vs. TT: 22.0%, P = 0.005), but not in the low FA group (CC 9.9% vs. TT 11.2%, P = 0.989). Conclusions: This study demonstrated that MTHFR C677T polymorphism can not only affect homocysteine concentration at baseline and post-FA treatment, but also can modify therapeutic responses to various dosages of FA supplementation.

AB - Background: This study aimed to investigate if the homocysteine-lowering efficacy of two commonly used physiological doses (0.4 mg/d and 0.8 mg/d) of folic acid (FA) can be modified by individual methylenetetrahydrofolate reductase (MTHFR) C677T and/or methionine synthase (MTR) A2756G polymorphisms in hypertensive Chinese adults. Methods. A total of 480 subjects with mild or moderate essential hypertension were randomly assigned to three treatment groups: 1) enalapril only (10 mg, control group); 2) enalapril-FA tablet [10:0.4 mg (10 mg enalapril combined with 0.4 mg of FA), low FA group]; and 3) enalapril-FA tablet (10:0.8 mg, high FA group), once daily for 8 weeks. Results: After 4 or 8 weeks of treatment, homocysteine concentrations were reduced across all genotypes and FA dosage groups, except in subjects with MTR 2756AG /GG genotype in the low FA group at week 4. However, compared to subjects with MTHFR 677CC genotype, homocysteine concentrations remained higher in subjects with CT or TT genotype in the low FA group (P <0.05 for either of these genotypes) and TT genotype in the high FA group (P <0.05). Furthermore, subjects with TT genotype showed a greater homocysteine-lowering response than did subjects with CC genotype in the high FA group (mean percent reduction of homocysteine at week 8: CC 10.8% vs. TT: 22.0%, P = 0.005), but not in the low FA group (CC 9.9% vs. TT 11.2%, P = 0.989). Conclusions: This study demonstrated that MTHFR C677T polymorphism can not only affect homocysteine concentration at baseline and post-FA treatment, but also can modify therapeutic responses to various dosages of FA supplementation.

KW - Folic acid supplementation

KW - Homocysteine-lowering efficacy

KW - MTHFR C677T polymorphism

KW - MTR A2756G polymorphism

UR - http://www.scopus.com/inward/record.url?scp=84855493917&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855493917&partnerID=8YFLogxK

U2 - 10.1186/1475-2891-11-2

DO - 10.1186/1475-2891-11-2

M3 - Article

C2 - 22230384

AN - SCOPUS:84855493917

VL - 11

JO - Nutrition Journal

JF - Nutrition Journal

SN - 1475-2891

IS - 1

M1 - 2

ER -